Trial · NCT00748657
Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
NCT00748657, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2015-06-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary. Trials, record NCT00748657. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00748657
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary
- NCT number
- NCT00748657
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 36 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types, Ovarian Steroid Cell Tumor
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis
- First posted
- 2008-09-08
- Last updated
- 2019-07-23
- Results first posted
- 2015-06-10
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Response | Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels | Complete and Partial Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 |
| Secondary | Progression-free Survival | Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels | Progression-Free Survival is the period from study entry until disease progression, death or date of last contact. |
| Secondary | Overall Survival | From study entry to death or last contact, up to 5 years. | The observed length of life from entry into the study to death or the date of last contact. |
| Secondary | Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Up to 5 years | Adverse Events at least possibly related to study agent. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Response | Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels | Eligible and Treated Patients | percentage of patients | NUMBER |
| SECONDARY | Progression-free Survival | Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels | Eligible and Treated Patients | Months | MEDIAN |
| SECONDARY | Overall Survival | From study entry to death or last contact, up to 5 years. | Eligible and treated patients. | Months | MEDIAN |
| SECONDARY | Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Up to 5 years | Eligible and evaluable patients | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group165
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Response | Bevacizumab | 16.7 | 90% Confidence Interval 7.5 to 30.3 | percentage of patients | |
| Progression-free Survival | Bevacizumab | 9.3 | 95% Confidence Interval 4.1 to 15.0 | Months | |
| Overall Survival | Bevacizumab | NA | 95% Confidence Interval 44.9 to NA | Months | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 0 | Leukopenia | 32 | Participants | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 1 (CTCAE v 3.0) | Leukopenia | 2 | Participants | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 2 (CTCAE v 3.0) | Leukopenia | 1 | Participants | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 3 (CTCAE v 3.0) | Leukopenia | 1 | Participants | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 4 (CTCAE v 3.0) | Leukopenia | 0 | Participants | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 5 (CTCAE v 3.0) | Leukopenia | 0 | Participants | |
| Number of Participants With Episodes and Grade of Adverse Events as Assessed by Common Terminology for Adverse Events Version 3.0 | Grade 0 | Thrombocytopenia | 28 | Participants |
1 to 10 of 165Source ClinicalTrials.gov
See all 165 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab | 36 | |
| Overall Study | COMPLETED | Bevacizumab | 36 | |
| Overall Study | NOT COMPLETED | Bevacizumab | 0 |
Source ClinicalTrials.gov
Adverse events170
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergy/Immunology - Other | Immune system disorders | Bevacizumab | 1 | 36 | |
| other | Allergic Reaction/Hypersensitivity | Immune system disorders | Bevacizumab | 1 | 36 | |
| other | Rhinitis | Immune system disorders | Bevacizumab | 11 | 36 | |
| other | Hearing (Without Monitoring Program) | Ear and labyrinth disorders | Bevacizumab | 3 | 36 | |
| other | Tinnitus | Ear and labyrinth disorders | Bevacizumab | 6 | 36 | |
| other | Platelets | Blood and lymphatic system disorders | Bevacizumab | 8 | 36 | |
| other | Blood/Bone Marrow - Other | Blood and lymphatic system disorders | Bevacizumab | 1 | 36 | |
| other | Leukocytes | Blood and lymphatic system disorders | Bevacizumab | 4 | 36 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Bevacizumab | 2 | 36 | |
| other | Hemoglobin | Blood and lymphatic system disorders | Bevacizumab | 15 | 36 |
1 to 10 of 170Source ClinicalTrials.gov
See all 170 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab | ||
| Total, other adverse events | Bevacizumab | 36 | 36 |
| Total, serious adverse events | Bevacizumab | 13 | 36 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| U10CA180868 | NRG Oncology Network Group Operations Center | WOLMARK, NORMAN; Le, Quynh-Thu Xuan; MANNEL, ROBERT S. | NRG ONCOLOGY FOUNDATION, INC. | NATIONAL CANCER INSTITUTE | 2014 to 2026 | NIH RePORTER |
| U10CA027469 | Gynecologic Oncology Group | DISAIA, PHILIP J. | GYNECOLOGIC ONCOLOGY GROUP | NATIONAL CANCER INSTITUTE | 1985 to 2013 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00748657
GET https://conductscience.org/api/trials/v1/NCT00748657/results?page=2